News

News Subscription

Sep 16. 2025 / Ad hoc announcement
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Read more
Download
Aug 19. 2025 / Ad hoc announcement
Basilea on track with strong 2025 half-year results
Read more
Download
Aug 14. 2025 / Ad hoc announcement
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
Read more
Download
Jul 29. 2025
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
Read more
Download
Jul 08. 2025 / Ad hoc announcement
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Read more
Download
Jun 05. 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
Read more
Download
May 20. 2025
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
Read more
Download
Apr 24. 2025
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
Read more
Download
Apr 16. 2025
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Read more
Download
Apr 16. 2025
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
Read more
Download